NAPSR news: Bayer Healthcare retains positive Q2 report from pharmaceutical sales

Bayer Group had an impressive second quarter for 2014 as earnings climbed based on successful drug launches and the company's established product pipeline.
Spread the Word
Listed Under

* Napsrx
* Napsr
* Cnpr Certification
* Pharmaceutical Sales
* Sales Marketing

* Health
* Medical

* Washington - District of Columbia - US

WASHINGTON - July 30, 2014 - PRLog -- The Bayer Group has reported an increase in profits compared to last year based on their 2014 Q2 Report. Net income rose 13.3%to 953 million euros ($1.27 billion) while worldwide sales amounted to 10.5 billion euros ($14 billion). Primary growth was a result of the company’s pharmaceuticals division. "Our life science businesses, in particular, saw unabated growth momentum, with very encouraging sales gains for our recently launched pharmaceutical products and our North and Latin American Crop Science business," Chief Executive Marijn Dekkers said in a statement.  According to the company, the pharmaceuticals Sector grew by 10% (Fx & portfolio adj.)  to EUR 2,960 million. Key conributors  to sales growth include: the anticoagulant Xarelto™, the eye medicine Eylea™, the cancer drugs Stivarga™ and Xofigo™, and Adempas™ to treat pulmonary hypertension.  Bayer's top selling drug Xarelto  had an impressive sales growth of 79.3 %.

Other pharmaceutical products that added to the growth include: Sales of Mirena,  the hormone-releasing intrauterine device increased by 13.1%, Sales of Aspirin™ Cardio for secondary prevention of heart attacks improved by 8.9%, the cancer drug Nexavar™  had an increase in sales by 3.4%. Sales also increased in the U.S. for the YAZ™/ Yasmin™/Yasminelle™, a line of oral contraceptives.

With such industry leaders posting gains in profitability from their successful product pipeline, they will need both certified and qualified individuals to promote their diversified therapeutic portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.

The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.

Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives (NAPSRx) for more information.

Email:*** Email Verified
Tags:Napsrx, Napsr, Cnpr Certification, Pharmaceutical Sales, Sales Marketing
Industry:Health, Medical
Location:Washington - District of Columbia - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Daily News
Weekly News

Like PRLog?
Click to Share